# EDGAR Filing Document

**Accession Number:** 0001347242
**File Stem:** 0001753926-23-000103
**Filing Date:** 2023-2
**Character Count:** 23434
**Document Hash:** b5661ea2d9045d744a1ef391b6130ef0
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001753926-23-000103.hdr.sgml**: 20230202

**ACCESSION NUMBER**: 0001753926-23-000103

**CONFORMED SUBMISSION TYPE**: 8-K/A

**PUBLIC DOCUMENT COUNT**: 32

**CONFORMED PERIOD OF REPORT**: 20230111

**ITEM INFORMATION**: Financial Statements and Exhibits

**FILED AS OF DATE**: 20230202

**DATE AS OF CHANGE**: 20230202

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** LIPELLA PHARMACEUTICALS INC
- **CENTRAL INDEX KEY:** 0001347242
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **IRS NUMBER:** 000000000
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 8-K/A
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-41575
- **FILM NUMBER:** 23582357

**BUSINESS ADDRESS:**
- **STREET 1:** 400 N LEXINGTON ST
- **STREET 2:** STE LL103
- **CITY:** PITTSBURGH
- **STATE:** PA
- **ZIP:** 15208
- **BUSINESS PHONE:** 412-901-0315

**MAIL ADDRESS:**
- **STREET 1:** 400 N LEXINGTON ST
- **STREET 2:** STE LL103
- **CITY:** PITTSBURGH
- **STATE:** PA
- **ZIP:** 15208

?xml version="1.0" encoding="utf-8"?

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

**FORM 8-K/A**

**CURRENT REPORT**

**Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934**

Date of Report (Date of earliest event reported): **February 2, 2023 (January 11, 2023)**

**Lipella Pharmaceuticals Inc.**

(Exact name of registrant as specified in its charter)

---

| | | |
|:---|:---|:---|
| **Delaware** | **005-93847** | **20-2388040** |
| (State or other jurisdiction<br> of incorporation) | (Commission File Number) | (IRS Employer<br> Identification No.) |

---

---

| | |
|:---|:---|
| **7800 Susquehanna St.,Suite 505**<br> **Pittsburgh, PA** | **15208** |
| (Address of registrant's principal executive office) | (Zip code) |

---

Registrant's telephone number, including area code: **(412) 901-0315**

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

---

| | | |
|:---|:---|:---|
| **Title of each class** | **Trading Symbol(s)** | **Name of each exchange on which**<br> **registered** |
| Common Stock, par value $0.0001 per share | LIPO | The Nasdaq Stock Market LLC |

---

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

**Explanatory Note**

This Current Report on Form 8-K/A is being filed as an amendment (this "Amendment No. 1") to the Current Report on Form 8-K filed by Lipella Pharmaceuticals Inc. (the "Company") with the U.S. Securities and Exchange Commission on January 12, 2023 (the "Original Filing"), solely for the purpose of correcting the investor presentation furnished as Exhibit 99.2 thereto (the "Investor Presentation"). The Original Filing mistakenly included an earlier version of the Investor Presentation and did not include the version that was used at the presentation, which included additional slides.

The information contained in this Amendment No. 1, including Exhibit 99.1 attached hereto, is deemed to be "furnished" and shall not be deemed to be "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), and shall not be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended (the "Securities Act"), or the Exchange Act, whether made before or after the date hereof, except as shall be expressly set forth by specific reference to this Amendment No. 1 in such filing. The information set forth in this Amendment No. 1 and Exhibit 99.1 attached hereto shall not be deemed an admission as to the materiality of any information in this Amendment No. 1 that is required to be disclosed solely to satisfy the requirements of Regulation FD.

**Forward-Looking Statements**

Exhibit 99.1 attached hereto contains, and may indicate, forward-looking statements within the meaning of Section 27A of the Securities Act, Section 21E of the Exchange Act and as defined in the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking statements include, but are not limited to, statements that express the Company's intentions, beliefs, expectations, strategies, predictions or any other statements related to the Company's future activities, or future events or conditions, including without limitation, those statements relating to the Company's clinical trial results for LP-10 in the updated Investor Presentation attached as Exhibit 99.1 hereto, or the Company's clinical trials and/or trial results for its other products now or in the future, which can be identified by terminology such as "may," "will," "expects," "anticipates," "aims," "potential," "future," "intends," "plans," believes," "estimates," "continue," "likely to," and other similar expressions intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. These statements are not historical facts and are based on current expectations, estimates and projections about the Company's business based, in part, on assumptions made by its management. These statements are not guarantees of future performance and involve risks, uncertainties and assumptions that are difficult to predict, many of which are beyond the Company's control. Any forward-looking statements speak only as of the date on which they are made, and the Company undertakes no obligation to update any forward-looking statement to reflect events or circumstances after the date of this Amendment No. 1, except as required by applicable law.

---

| | |
|:---|:---|
| **Item 9.01** | **Financial Statements and Exhibits.** |

---

(d) Exhibits

---

| | |
|:---|:---|
| **Exhibit No.** | **Description** |
| [99.1](g083377_ex99-1.htm) | [Lipella Pharmaceuticals Inc. Biotech Showcase 2023.](g083377_ex99-1.htm) |
| 104 | Cover Page Interactive Data File (embedded within the Inline XBRL document) |

---

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

---

| | | |
|:---|:---|:---|
| Date: February 2, 2023 | **Lipella Pharmaceuticals Inc.** | **Lipella Pharmaceuticals Inc.** |
|  | By: | /s/ Jonathan Kaufman |
|  |  | Name: Jonathan Kaufman<br> Title: Chief Executive Officer |

---

## Exhibit 99.1

**Exhibit 99.1**

![](img001.jpg)

Biotech Showcase 2023 San Francisco, CA January 11, 2003

Liposomal Drug Delivery to Mucosal Surfaces1

![](img002.jpg)

**Disclaimers**

The information in this presentation is being provided so you can familiarize yourself with Lipella Pharmaceuticals Inc. (together with its subsidiaries, "Lipella" the "Company," "we," "us," or "our") during this informational meeting. We request that you keep any information we provide at this meeting confidential and that you do not disclose any of the information to any other parties without the Company's prior express written permission. Although the Company believes the information contained herein is accurate in all material respects, the Company does not make any representation or warranty, either express or implied, as to the accuracy, completeness or reliability of the information contained in this presentation.

**Forward-Looking Statements**

The presentation includes certain "forward-looking statements." All statements, other than statements of historical fact, included in this presentation regarding, among other things, our strategy, future operations, financial position, anticipated dividends, projected costs, prospects, pipeline and opportunities, sources of growth, successful implementation of our proprietary technology, plans and objectives are forward-looking statements. Forward-looking statements can be identified by words such as "may," "will," "could," "continue," "would," "should," "potential," "target," "goal," "anticipates," "intends," "plans," "seeks," "believes," "estimates," "predicts," "expects," "projects" and similar references to future periods. Forward-looking statements are based on our current expectations and assumptions regarding future events and financial trends that we believe may affect our financial condition, results of operations, business strategy, short- and long-term business operations and objectives, and financial needs. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict. Our actual results may differ materially from those contemplated by the forward-looking statements. We caution you, therefore, against relying on any of these forward-looking statements. They are neither statements of historical fact nor guarantees or assurances of future performance. There are risks, uncertainties and other factors, both known and unknown, that could cause actual results to differ materially from those in the forward-looking statements which include, but are not limited to, regional, national or global political, economic, business, competitive, market and regulatory conditions, and other factors. Any forward-looking statement made by us is based upon the reasonable judgment of our management at the time such statement is made and speaks only as of the date on which it is made. Factors or events that could cause our actual results to differ may emerge from time to time, and it is not possible for us to predict all of them. We undertake no obligation to update any forward-looking statement, whether as a result of new information, future developments or otherwise, except as may be required by applicable law.

Nothing contained herein is, or shall be relied upon as, a promise or representation as to the past or future. The Company expressly disclaims any and all liability relating to or resulting from the use of this presentation. In addition, the information contained in this presentation is as of the date hereof, and the Company has no obligation to update such information, including in the event that such information becomes inaccurate. You should not construe the contents of this presentation or other information we provide at this meeting as legal, tax, accounting or investment advice or a recommendation. You should consult your own counsel and tax and financial advisors as to legal and related matters concerning the matters described herein.

![](img003.jpg)

**Executive Summary**

*Emerging, clinical-stage, proprietary 505(b)(2) opportunity*

Overview of Opportunity Drug-Delivery Focused Biotech

505(b)(2) Optimized for

LP-10 is a phase-2a, 505(b)(2) drug candidate for epithelial tissues

hemorrhagic cystitis Patented liposomal Lower systemic local drug delivery drug exposure

A platform proprietary drug delivery technology optimized for use with epithelial tissue efficient development strategy **NDA**

Issued patents in US, Canada, and Australia (valid to Potential for accelerated 2034), and an application pending in Europe. Pilot manufacturing approval pathways

Transferrable CMC Approved phase-2a IND

Potential applications include bladder, urethra, oral cavity, esophageal, and colonic

Impressive Revenue Potential

The LP-10 drug candidate for hemorrhagic cystitis has orphan drug designation from the FDA

**$20,000 annual $1.2 billion annual**

Completion of LP-10's open-label, dose-ranging, **revenue per patient<sup>7</sup> revenue potential<sup>8</sup>** phase 2(a) clinical trial is expected in 4Q 2022 **prostate and other pelvic radiation-**

**pelvic malignancies radiation therapy hemorrhagic cystitis**

LP-10 peak annual revenue estimates in hemorrhagic cystitis exceed $1 billion

**over 3,000,000 over 900,000 over 60,000** LP-10 is developed by an experienced management **survivors in US<sup>4</sup> survivors in US<sup>5</sup> patients per year<sup>6</sup>** team having decades of biotech industry experience (4) American Cancer Society Cancer Treatment and Survivorship Fact and Figures 2019-2021, (5) based on the Company's 30% estimate (6) 8% estimate, (7) based on the Company's estimate, (8) $20,000 average revenue per each of an estimated

3 60,000 patients treated per year.

![](img004.jpg)

**Company History**

*Born out of an NIH funded research collaboration on liposomal drug delivery to become a clinical-stage pharmaceutical company with a growing pipeline.* 

**2005 2008 2012 2020 2021 2022**

Jonathan Kaufman Michael Chancellor LP-10 FDA Orphan Platform patent Doug Johnston Initial Public co-founds Lipella joins Management Designation awarded VP. Finance Offering

**Nasdaq: LIPO**

**2007 2010 2019 2021 2021 2022**

initial NIH funding Michele Gruber LP-10 FDA Janet Okonski FDA advice LP-10 phase-2a received Operations IND Approval Clinical Director re. LP-310 completed

![](img005.jpg)

**Hemorrhagic Cystitis, Uncontrolled Urinary Blood Loss**

*Hemorrhagic cystitis is a serious, life-threatening bladder damage from pelvic radiation therapy and/or bladder-toxic chemotherapy.*

Millions of patients 20% of such An increasing US Years after Hemorrhagic are increasingly patients receive population is receiving cystitis is a diagnosed with pelvic radiation surviving cancer treatment, many potentially pelvic malignancies therapy during therapies, patients acquire chronic, highly including prostate the treatment of including pelvic hemorrhagic morbid condition cancer, and cancers their cancer, in radiation, and cystitis, with no approved of the uterine addition to chemotherapies uncontrolled drug therapy, and corpus, requiring surgery and that damage bladder blood a four percent treatment. chemotherapy. DNA. loss. mortality rate.

![](img006.jpg)

**Cancer Survivorship & Hemorrhagic Cystitis**

*Expected annual revenue per patient is **$20,000***

*Market penetration of 60,000 patients (45%) yields **$1.2 billion** annual revenue The current phase-2a is focused on radiation cystitis. LP-10 is also expected to address hemorrhagic cystitis from chemotherapy.*

**Prostate Cancer Uterine Corpus Cancers Rectal & Other Pelvic**

700,000<sup>1</sup> 200,000<sup>1</sup> 300,000<sup>1</sup>

Pelvic Radiation Survivors Pelvic Radiation Survivors Pelvic Radiation Survivors

42,000<sup>2</sup> 12,000<sup>2</sup> 18,000<sup>2</sup>

Severe HC Survivors Severe HC Survivors Severe HC Survivors

**Breast Cancer Leukemia & Lymphoma Other Tumors**

360,000<sup>1</sup> 180,000<sup>1</sup> 60,000<sup>1</sup>

x-DNA Chemotherapy Survivors x-DNA Chemotherapy Survivors x-DNA Chemotherapy Survivors

36,000<sup>2</sup> 18,000<sup>2</sup> 6,000<sup>2</sup>

Severe HC Survivors Severe HC Survivors Severe HC Survivors

(1) American Cancer Society Cancer Treatment and Survivorship Fact and Figures 2019-2021. (2) Based on the Company's estimate.

![](img007.jpg)

**LP-10 Stops Bleeding via Two Modes of Action**

*Tacrolimus' molecular mechanism includes calmodulin mediated t-cell inhibition*

**Reduce capillary Inhibits cytokine Increased efficacy blood flow cascade probability**

• **LP-10 is a potent** • **LP-10 is a potent Well-known vasoconstrictor anti-inflammatory pharmacologic mechanisms** • **reduces blood** • **Reduces tissue increase the flow to the injury in the probability of bladder lumen bladder efficacy.**

![](img008.jpg)

**LP-10 Product Form**

*Liposomal tacrolimus treatment for hemorrhagic cystitis*

**Sterile Easy powder to deliver**

**Low**

**COGS In-house CMC**

![](img009.jpg)

**LP-10 Phase 2a Trial Design Summary**

*Multi-center, dose-ranging study* 

**Details**

Refractory moderate-to-severe hemorrhagic

**Indication**

cystitis (HC)

Dose ranging study to evaluate safety,

**Protocol design**

tolerability, and efficacy of LP-10

**Subjects** 12 Male and Female subjects from 5 sites Up to 2 instillations of LP-10 (2, 4 and 8 mg)

**Treatment**

given within 3-7 days

**Patient Participation Time** 6 weeks following the initial procedure

![](img010.jpg)

**LP-10 Phase 2a Trial Design Summary**

***Key inclusion criteria: Key Exclusion criteria:***

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1. Males and females, at least 18
 years 1. Patients taking immunosuppressive

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2. History of sterile moderate to
 severe HC therapy

(Grades 2-4) for at least 3 months with at 2. History of interstitial cystitis/bladder pain least 1 episode of hematuria with or syndrome or hemorrhagic cystitis due to without clot infection (bacterial, viral or fungal)

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;3. Previous use of medications and/or
 3. Life expectancy less than 12 months treatment(s) for HC symptom relief 4. PSA
 > 4 ng/ml (measured within the last

3 months)

The ***primary safety endpoint*** is the incidence of treatment-related serious adverse events (SAEs) and the incidence of protocol-defined treatment or procedure related adverse events associated with the use of LP-10 as well as assess the pharmacodynamic (PD) effects and pharmacokinetic (PK) profile The ***primary efficacy endpoint*** of LP-10 therapy will be evaluated by assessing pre-post treatment changes in hematuria at baseline and primary endpoint at 1 week, and 2 weeks after final instillation

![](img011.jpg)

**LP-10 Phase 2a Trial Design Summary**

*Recruitment sites and subject disposition*

**Patient Disposition Number Comments**

Screened, n 15 14 male, 1 female Enrolled, n 13 13 male 2 instillations (n=10) Number of instillations 23 1 instillation (n=3) Discontinued, % 0 Withdrew consent, % 0 Lack of compliance, % 0 Lost to follow-up, % 0

![](img012.jpg)

**LP-10 Phase 2a Trial Design Summary**

*Patient Demographics*

**Mean Comment**

Age, years 67 Range 25-89 Race White 9 Non-White 4

Radiation induced HC 11 Chemotherapy induced HC 2 Cancer Prostate cancer 9 Bladder cancer 2 Lymphoma 2

Duration of HC years 4 Range 1 -14 years medication, HBO, catheters, Prior HC treatment 13 surgical procedures

![](img013.jpg)

**LP-10 Safety**

*Adverse events (AE)*

**Number Comment**

Product related significant adverse events 0 Subject discontinuations 0

Number of subjects with adverse events 5/13 11 AEs reported in 5 subjects

2 mg: 3 AEs in 2 subjects 4 mg: 2 AEs in 1 subject 8 mg: 6 AEs in 2 subjects

Bladder spasm, urinary urgency, pain and

dysuria

Weakness and dizziness 1 Low blood pressure 1 Flank pain 1 Urinary retention due to bladder blood clot 1 Headache 1 Arthralgia 1 Urinary tract infection 1

![](img014.jpg)

**LP-10 Pharmacokinetics and Safety**

*Local delivery of tacrolimus limits systemic distribution*

***Subject Group baseline 1 hour 2 hours 4 hours 48 hours***

• < 1.5 ng/ml 1 2 mg - - 1.5 - -

considered 2 2 mg - 2.3 - - -undetectable 3 2 mg - 3.0 1.7 - -

4 2 mg - 2.8 1.8 - -

• All Levels were 5 4 mg - 4.8 1.8 - -within the safe 6 4 mg - 6.1 4.0 - -range, < 15 ng/ml 7 4 mg - 2.9 2.0 - -

8 4 mg - 3.9 2.0 - -

&nbsp;&nbsp;&nbsp;&nbsp;• The 2 mg and 4 mg

9 8 mg - 2.2 2.1 - -

doses peaked at 1 10 8 mg - 3.0 - - -hour and cleared 11 8 mg - 3.0 5.4 2.7 -by 4 hours in all 12 8 mg - 5.0 3.6 1.6 -

subjects 13 8 mg - 7.3 3.8 - -

![](img015.jpg)

**LP-10 Responder Analysis**

*Evaluating cystoscopy, hematuria, and symptoms*

*(NR="no response", PR="partial response", CR="complete response") (normalized rank, 0 to 9)*

cystoscopy hematuria

&nbsp;&nbsp;&nbsp;&nbsp;• Efficacy CR in all subjects symptoms

improvement reported by principal **9**

**8**

investigators, **7** patients and **6** laboratory assays **5**

**4**

&nbsp;&nbsp;&nbsp;&nbsp;• Improvement of **3** hematuria
 consistent **2** 

with cystoscopic normalized response rank **1**

evidence of bleeding **0**

and ulceration NR in all subjects 2 mg 4 mg 8 mg

treatment group

![](img016.jpg)

**LP-10 Phase 2a Trial Conclusion**

**Trial Summary**

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• LP-10 safety:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• No Product related SAEs

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Instillation procedure well
 tolerated by all subjects

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• LP-10 pharmacokinetic analysis
 demonstrated very short duration of systemic uptake

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Signal of efficacy and dose
 response

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Hematuria improved, decreased
 cystoscopic bleeding and ulceration sites and improved patients' urinary symptoms

**Next Step**

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Successful completion of first
 in man Phase 2a multicenter clinical trial

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Minimal effective dose data
 to report to the FDA

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Request Accelerate/breakthrough
 P3 Design

![](img017.jpg)

**Asset Pipeline and LP-310**

*LP-310: Liposomal tacrolimus for oral lichen planus*

Product Target Marketing Next Anticipated Candidate Indication Preclinical Phase 1 Phase 2 Phase 3 Approval Milestone

Hemorrhagic FDA Meeting LP-10 Cystitis 3Q23

Oral Lichen IND submission LP-310 Planus 2Q23

Oral rinse formulation of LP-10

Increased local concentration in oral cavity while minimalizing systemic toxicity 505(b)(2) pathway, platform technology expansion Low COGS and fast development plan **LP-310** Large market size opportunity (6 million US) with no current approved therapy Comparator: AFYX's buccal steroid patch in Phase 3 trial **Oral Lichen Planus** Completed Type B pre-IND meeting (PIND 155011) April 08, 2021 **Mouth Rinse** IND preparation for Phase 2a multicenter dose escalation study

![](img018.jpg)

Liposomal Drug Delivery to Mucosal Surfaces

![](img019.jpg)

Lipella Pharmaceuticals Inc. 7800 Susquehanna Street, Suite 505 Pittsburgh, PA 15208 412-894-1853 www.lipella.com